Get the Stockscreener App
11.12
5.60%
0.59
Bicara Therapeutics Inc stock is traded at $11.12, with a volume of 541.41K.
It is up +5.60% in the last 24 hours and up +23.15% over the past month.
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
See More
Previous Close:
$10.53
Open:
$10.58
24h Volume:
541.41K
Relative Volume:
0.67
Market Cap:
$606.44M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-5.84%
1M Performance:
+23.15%
6M Performance:
-9.15%
1Y Performance:
+0.00%
1-Day Range:
$10.40
$11.13
1-Week Range:
$10.40
$11.94
52-Week Range:
$7.80
$28.09
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Name
Bicara Therapeutics Inc
Sector
Industry
Phone
617-785-8308
Address
245 MAIN STREET, CAMBRIDGE
Compare BCAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
11.12 | 574.27M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 118.67B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.54 | 59.23B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
419.56 | 52.67B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
690.32 | 41.24B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
304.30 | 32.36B | 3.81B | -644.79M | -669.77M | -6.24 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-23-25 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Apr-17-25 | Initiated | Wells Fargo | Underweight |
| Feb-06-25 | Initiated | Wedbush | Outperform |
| Dec-06-24 | Initiated | H.C. Wainwright | Buy |
| Nov-05-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-08-24 | Initiated | Morgan Stanley | Overweight |
| Oct-08-24 | Initiated | Stifel | Buy |
| Oct-08-24 | Initiated | TD Cowen | Buy |
View All
Bicara Therapeutics Inc Stock (BCAX) Latest News
Price Channel Expanding on Bicara Therapeutics Inc.’s ChartTrade Timing Strategy With Technical Data Explained - metal.it
Is Bicara Therapeutics Inc. stock overvalued or undervaluedStrong return on investment - Jammu Links News
How volatile is Bicara Therapeutics Inc. stock compared to the marketMaximize returns with disciplined trading - Jammu Links News
What analysts say about Bicara Therapeutics Inc. stockUnprecedented profits - Jammu Links News
What is Bicara Therapeutics Inc. company’s growth strategyMaximize gains with expert analysis - Jammu Links News
What are the latest earnings results for Bicara Therapeutics Inc.Exceptional stock performance - Jammu Links News
How does Bicara Therapeutics Inc. compare to its industry peersPhenomenal capital appreciation - Jammu Links News
Does Bicara Therapeutics Inc. stock perform well during market downturnsTake advantage of unprecedented market momentum - Jammu Links News
Is Bicara Therapeutics Inc. the Top Chart Pick This WeekEntry Points For Growing Stocks Identified by Models - beatles.ru
Is it the right time to buy Bicara Therapeutics Inc. stockBreakout Stocks Tips That Work - jammulinksnews.com
What institutional investors are buying Bicara Therapeutics Inc. stockLow Risk Recommendation That Work - Jammu Links News
Will Bicara Therapeutics Inc. Benefit From Broader Market BounceROI Boosting Trade Opportunity Calendar Published - metal.it
Bicara Therapeutics Inc. Inches Above Key Support — Safe to HoldWealth Building Stock Market Ideas Based on Momentum - metal.it
RSI Crosses Above 30 for Bicara Therapeutics Inc. — Reversal in SightGrowth Based Investment Plan Guidance Highlighted - metal.it
Bicara Therapeutics Inc. Shows Risk Reward Favoring UpsideEntry Alert Based on Volume Spikes Detected - metal.it
Will Bicara Therapeutics Inc. Recover After Recent DeclineConservative Entry for High Return Setup Backed - beatles.ru
When is Bicara Therapeutics Inc. stock expected to show significant growthSmart Portfolio Strategy For Beginners - jammulinksnews.com
How Bicara Therapeutics Inc. stock performs during market volatilityValue Investing Picks With Stability Outlined - metal.it
Bicara Therapeutics Inc. Stock Approaches Key Moving AverageROI Driven Equity Selection With Safety Emphasized - metal.it
Real time breakdown of Bicara Therapeutics Inc. stock performanceDaily Stock Forecast Powered by AI Tools - Newser
Why is Bicara Therapeutics Inc. stock attracting strong analyst attentionGain access to exclusive stock analysis - jammulinksnews.com
Bicara Therapeutics Inc. Stock Performance After Earnings: Historical InsightsDefensive Stock Picks with Upside - Newser
Is Bicara Therapeutics Inc. a good long term investmentExceptional stock performance - PrintWeekIndia
What drives Bicara Therapeutics Inc. stock priceSky-high return potential - PrintWeekIndia
What analysts say about Bicara Therapeutics Inc. stock outlookSuperior investment outcomes - Jammu Links News
Is Bicara Therapeutics Inc. stock a good hedge against inflationExtraordinary profit generation - jammulinksnews.com
Will Bicara Therapeutics Inc. stock benefit from interest rate changesDynamic investment growth - Jammu Links News
Bicara Therapeutics Inc. Stock Analysis and ForecastFree Investment Community - jammulinksnews.com
Bicara Therapeutics Inc Stock (BCAX) Financials Data
There is no financial data for Bicara Therapeutics Inc (BCAX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
3.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):